Michael C Donegan insider trades: TherapeuticsMD (TXMD) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 27, 2023 | TXMD | ↓ Sell | 1,697 | $5.08 | $9K | Direct | Jan 30, 2023 (3d) |
| Jan 24, 2023 | TXMD | ↓ Sell | 1,309 | $5.34 | $7K | Direct | Jan 25, 2023 (1d) |
| Dec 6, 2022 | TXMD | ↓ Sell | 910 | $4.78 | $4K | Direct | Dec 9, 2022 (3d) |
| Nov 30, 2021 | TXMD | ↓ Sell | 29,790 | $0.54 | $16K | Direct | Dec 2, 2021 (2d) |
| May 11, 2021 | TXMD | ↓ Sell | 4,842 | $1.04 | $5K | Direct | May 12, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Michael C Donegan's insider trades
Michael C Donegan is Prin. Fin. and Acctg. Officer at TherapeuticsMD (TXMD). Since May 11, 2021, Michael has reported no open-market purchases and 5 sales worth $41K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (11 filings), option exercises (6 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TXMD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.